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RESUMO 
 
O ameloblastoma é um tumor odontogênico benigno, porém com comportamento local 
agressivo devido seu potencial de infiltração e destruição óssea, afetando preferencialmente a 
região posterior de mandíbula. A sua contraparte maligna, o carcinoma ameloblástico, pode 
surgir de novo ou desenvolver-se de um ameloblastoma prévio, estando associado a um alto 
índice de recidivas e metástases linfonodal e a distância. Embora sejam raros, ambos 
representam os tumores odontogênico benigno e maligno mais frequentemente diagnosticados 
nos principais serviços de Patologia Oral. Os mecanismos moleculares envolvidos com a 
etiopatogenia destes tumores são pouco conhecidos, e apesar de alterações no sistema de 
reparo de erros de pareamento de bases do DNA, conhecido como sistema mismatch (MMR) 
favorecerem o desenvolvimento de diferentes neoplasias humanas, a importância destes no 
desenvolvimento do ameloblastoma e do carcinoma ameloblástico ainda carece de estudos. O 
MMR humano compreende o conjunto de proteínas divididas em dois grupos, hMutS e 
hMutL. Sua principal função é de corrigir erros de pareamentos e de loops de inserção e 
deleção das bases nitrogenadas no DNA. Uma variedade de neoplasias e condições 
potencialmente malignas possuem alteração desse sistema. Os objetivos deste trabalho estão 
divididos em capítulos e compreendem: (i) conceituar a função das proteínas do sistema 
mismatch nas lesões neoplásicas humanas, com ênfase nas que acometem a região oral; (ii) 
analisar quantitativamente a imunoexpressão das proteínas hMutS em germes dentais 
humanos, ameloblastomas e carcinomas ameloblásticos, correlacionando seus resultados com 
a expressão de BRAF-V600E e com a recorrência tumoral. Foi observado que expressão 
imunohistoquímica das proteínas hMutS em 10 amostras de germes dentais humanos, 39 
ameloblastomas e 2 carcinomas ameloblásticos apresentam um decréscimo sequencial nos 
níveis de expressão nos grupos analisados, especialmente das proteínas hMSH2 e hMSH6 em 
ameloblastomas (p=0.0059) em relação ao germe dental humano (p<0.0001). A expressão 
imunohistoquímica das proteínas hMutS em 73 amostras de ameloblastomas contidas em um 
bloco de 1.0 mm de tissue microarray permitiu associar seus resultados com a taxa de 
recorrências e presença da mutação BRAF-V600E. Os casos de ameloblastomas com 
sobrexpressão das proteínas hMSH2, hMSH3 apresentaram a presença de BRAF-V600E 
(p<0.05) e foram associados com a recorrência da lesão (p=0.035). Estes dados sugerem que a 
sobrexpressão de hMutS pode estar indiretamente relacionada mecanismos moleculares e 
genéticos envolvidos na progressão e recorrência tumoral. 
Palavras-chave: ameloblastoma; tumores odontogênicos; hMSH2; hMSH3; hMSH6; proteínas 
mismatch. 
ABSTRACT 
 
Ameloblastoma is a benign odontogenic tumor, but with aggressive local behavior due to its 
potential for infiltration and bone destruction, preferentially affecting the posterior region of 
the mandible. Its malignant counterpart, ameloblastic carcinoma, may arise de novo or 
develop from a previous ameloblastoma, being associated with a high rate of relapses and 
lymph node metastases and distance. Although rare, they both represent the benign and 
malignant odontogenic tumors most frequently diagnosed in the main Oral Pathology 
services. The molecular mechanisms involved in the etiopathogenesis of these tumors are 
poorly understood, and although alterations in the DNA bases pairings repair system, known 
as the mismatch system (MMR), favor the development of different human neoplasms, the 
importance of these in the development of ameloblastoma and ameloblastic carcinoma still 
lacks studies. Human MMR comprises the set of proteins divided into two groups, hMutS and 
hMutL. Its main function is to correct errors of pairings and loops of insertion and deletion of 
the bases in the DNA. Several neoplasms and potentially malignant conditions have alteration 
of this system. The objectives of this work are divided into chapters and include: (i) 
conceptualizing the function of the proteins of the mismatch system in human neoplastic 
lesions, with emphasis on those that affect the oral region; (ii) quantitatively analyze the 
immunoexpression of hMutS proteins in human dental germs, ameloblastomas and 
ameloblastic carcinomas, correlating their results with the expression of BRAF-V600E and 
with tumor recurrence. Immunohistochemical expression of hMutS proteins in 10 human 
dental germ samples, 39 ameloblastomas and 2 ameloblastic carcinomas showed a sequential 
decrease in expression levels in the analyzed groups, especially the hMSH2 and hMSH6 
proteins in ameloblastomas (p = 0.0059) in relation to human dental germ (p <0.0001). The 
immunohistochemical expression of hMutS proteins in 73 samples of ameloblastomas 
contained in a 1.0 mm block of tissue microarray allowed to associate their results with the 
rate of recurrences and the presence of the BRAF-V600E mutation. The cases of 
ameloblastomas with overexpression of the hMSH2, hMSH3 proteins showed the presence of 
BRAF-V600E (p <0.05) and were associated with lesion recurrence (p = 0.035). These data 
suggest that the overexpression of hMutS may be indirectly related molecular and genetic 
mechanisms involved in tumor progression and recurrence. 
Keywords: ameloblastoma; odontogenic tumors; hMSH2; hMSH3; hMSH6; mismatch 
proteins. 
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1 INTRODUÇÃO 
1.1 Ameloblastoma 
 O ameloblastoma é um tumor odontogênico epitelial sem a formação de tecido 
mineralizado que se origina de remanescentes de tecido odontogênico como a lâmina dentária, 
órgão do esmalte, restos de Malassez e do revestimento epitelial de cistos odontogênicos, 
especialmente os cistos dentígeros. (Dhanuthai et al., 2012; Masthan et al., 2015; McClary et 
al., 2016). Primeiramente descrito por Cusack (1827), esta rara neoplasia acomete os ossos 
gnáticos e representa cerca de 1% de todos os tumores orais, variando entre 9% – 11% dentre 
os tumores odontogênicos (Masthan et al., 2015). Apresenta pico de ocorrência entre os 30-60 
anos de idade, sem predileção pelo gênero e com incidência global de 0,5 casos/milhão/ano 
(Fregnani et al., 2002; McClary et al., 2016). As manifestações clínicas apresentam 
sintomatologia discreta, normalmente associada a um crescimento de volume indolor e lento, 
porém localmente agressivo e infiltrativo, resultando em alta taxa de recorrência. Possui forte 
predileção pela mandíbula em relação à maxila (13:1), preferencialmente a região posterior e 
em terceiros molares não erupcionado (Dhanuthai et al., 2012). É radiograficamente 
observado como imagens radiolúcidas uniloculares ou multiloculares, podendo apresentar 
deslocamentos e reabsorções dentárias (Dhanuthai et al., 2012; McClary et al., 2016). Quando 
associado às características microscópicas, pode ser classificado como ameloblastoma 
unicístico, sólido ou multicistico (a maioria dos casos) ou periférico, apresentando seus 
padrões histológicos variáveis (Dhanuthai et al., 2012; Masthan et al., 2015; McClary et al., 
2016). 
A abordagem cirúrgica representa o tratamento padrão para o ameloblastoma, 
porém os índices de recidiva da lesão estão fortemente relacionados com a modalidade 
terapêutica empregada. No ameloblastoma unicístico, a taxa de recorrência corresponde a 4% 
para o tratamento radical, como a ressecção em bloco, contra 17% do tratamento conservador, 
como a curetagem da lesão, enquanto que no multicístico temos um índice de recorrências de 
8% quando utilizado tratamento radical contra 38% quando tratamentos conservadores são 
realizados (Antonoglou and Sándor, 2015). 
 
1.2 Carcinoma ameloblástico 
Os tumores odontogênicos malignos são neoplasias raras que correspondem a 
menos de 6% de todos os tumores odontogênicos nas principais séries epidemiológicas 
publicadas. Dentre estas lesões raras, o carcinoma ameloblástico corresponde ao tumor 
odontogênico maligno mais comumente diagnosticado, com uma incidência estimada de 
apenas 1,79 casos para cada 10 milhões de pessoas/ano. Esta neoplasia combina as 
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características histológicas do ameloblastoma com diferentes graus de atipia celular. Pode 
surgir de novo, sem uma neoplasia benigna prévia, ou desenvolver-se de um cisto ou tumor 
odontogênico benigno pré-existente, como um ameloblastoma, recebendo a denominação de 
carcinoma ameloblástico secundário (Hall et al., 2007; Pirklbauer et al., 2012). 
Embora sua apresentação clínica seja variável, uma tumefação local de 
crescimento rápido, associada a dor e parestesia, são as manifestações mais relatadas. Possui 
ligeira predileção pelo sexo masculino, com idade média de 40 anos, tendo a região posterior 
da mandíbula como o sítio mais afetado. Radiograficamente apresenta imagens radiolúcidas 
mal definidas, com eventuais focos radiopacos sugestivos de calcificações distróficas, 
podendo causar reabsorções e deslocamentos dentários (Benlyazid et al., 2007). A análise 
histológica do carcinoma ameloblástico demonstra regiões de diferenciação ameloblástica 
com graus variáveis de pleomorfismo e atipia celular, além de figuras de mitose atípicas, 
necrose tecidual e eventuais focos de invasão perineural (Fitzpatrick et al., 2015; Lucca et al., 
2010). 
Pouco se conhece sobre suas alterações genéticas ou moleculares, o que limita o 
aprimoramento da abordagem terapêutica desta entidade. Portanto, os pacientes são tratados 
por meio de abordagem cirúrgicas radicais, como a remoção em bloco do tumor ou a ampla 
ressecção com margens de segurança, causando um elevado grau de morbidade terapêutica. 
Além disso, altos índices de recorrência que variam de 28,3% a 90% são relatados na 
literatura dependendo em especial da abordagem cirúrgica empregada. A frequência de 
metástases a distância chega a 22% e os locais mais acometidos são o pulmão, cérebro e 
múltiplos ossos. O prognóstico é considerado sombrio com taxas de sobrevida após cinco 
anos próximas de 70%, diminuindo para cerca de 20% em pacientes com metástases 
(Benlyazid et al., 2007; Hall et al., 2007). 
 
1.3 Sistema de reparo mismatch 
Os mecanismos genéticos envolvidos nessas manifestações neoplásicas ainda são 
pouco compreendidos. Uma das linhas de estudo pouco explorada está relacionada com o 
sistema de reparo de bases nitrogenadas mal pareadas do DNA, conhecido como sistema 
mismatch (MMR). O mecanismo deste sistema é mediado pela associação de proteínas que 
mantêm a fidelidade do material genético replicado, corrigindo erros no pareamento de bases 
e impedindo a instabilidade de microssatélites. O sistema humano é homólogo ao encontrado 
em na bactéria Escherichia coli (E. coli), sendo denominados homólogos MutS (hMutS) e 
MutL (hMutL) (Hsieh and Yamane 2008). Em tumores odontogênicos, o estudo deste 
mecanismo foi apenas abordado por Castrilli et al. (2001) de forma descritiva através de 
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estudo imunohistoquímico em 25 casos de ameloblastomas. Neste estudo, os autores 
identificaram a expressão positiva das proteínas hMSH2 e hMLH1 (componentes dos grupos 
hMutS e hMutL, respectivamente), mas não realizaram estudos quantitativos ou comparativos 
com germes dentais humanos, por exemplo. 
Neste contexto, propusemos um estudo mais aprofundado da expressão 
imunohistoquímica das proteínas relacionadas ao sistema mismatch em ameloblastomas e 
carcinomas ameloblásticos, tendo como controle o epitélio ameloblástico normal de germes 
dentais humanos, comparando seus resultados e correlacionando-os com as características 
clínicas e potencial prognóstico. 
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Abstract 
Different environmental agents may cause DNA mutations by disrupting its double-
strand structure; however, even normal DNA polymerase function may synthesize 
mismatch nucleotide bases, occasionally demonstrating failure in its proofreading 
activity. To overcome this issue, mismatch repair (MMR) system, a group of proteins 
specialized in finding mispairing bases and small loops of insertion or deletion, 
works to avoid the occurrence of mutations that could ultimately lead to innumerous 
human diseases. In the last decades, the role of MMR proteins in oral carcinogenesis 
and in the development of other oral cavity neoplasms has grown, but their importance 
in the pathogenesis and their prognostic potential for patients affected by oral 
malignancies, especially oral squamous cell carcinoma (OSCC), remain unclear. 
Therefore, in this manuscript we aimed to review and critically discuss the currently 
available data on MMR proteins expression in oral potentially malignant lesions, in 
OSCC, and in other oral neoplasms to better understand their relevance in these lesions.   
Keywords: leukoplakia; mismatch repair system; MLH; MSH; MutL; MutS; oral cancer 
 
Introduction 
It is known that different endogenous and exogenous agents may cause DNA 
mutations by disrupting its double-strand structure (1); however, DNA damage can also be 
originated because of natural replication errors, including failures of DNA polymerase 
activity (2) that may incorporate mismatched nucleotide bases, predisposing individuals to 
innumerous human diseases (3). 
Twelve different single-base incorporated errors can be found (4). Because these 
genetic errors may pass unnoticed by the proofreading activity of DNA polymerase, the post- 
replicated DNA strand is additionally checked by a mismatch repair (MMR) system that 
consists of a group of proteins specialized in finding not only mispairing bases, but also small 
loops of insertion or deletion, and ultimately providing their corrections (5). 
Important new data were provided on the structure and function of MMR in the 
human genome stability, but its importance on the development of different malignant and 
potentially malignant human diseases has only recently been investigated. Therefore, in this 
manuscript we aimed to review the current data available on MMR expression pattern and its 
importance for the progression of oral squamous cell carcinoma (OSCC) and oral potentially 
malignant lesions, as well as to provide an overview on their importance for the pathogenesis 
of other oral cavity neoplasms. 
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MMR system and your proteins 
Mismatch repair system was initially investigated in Escherichia coli, being 
classified in four different groups as MutS, MutL, MutH, and MutU (6), whereas following 
studies in eukaryotic cells defined only two homologous groups, hMutS and hMutL (7), 
which include the somatic human proteins hMSH2 (gen locus on 2p21), hMSH3 (5q14.1), 
hMSH4 (1p31), hMSH5 (6p21.3), hMSH6 (2p16), hMLH1 (3p21), hPMS1 (2q31.1), hPMS2 
(7q22.2), and hMLH3 (14q24.3) (8, 9). 
Although bacterial MutS and MutL groups are formed by homodimers, in 
eukaryotic cells these groups comprise heterodimers composed by two related, but distinct 
protein subunits (10). hMutS contains the heterodimers hMSH2- hMSH6 (called hMutSα) and 
hMSH2-hMSH3 (called hMutSβ), whereas hMutL contains the heterodimers hMLH1-hPMS2 
(hMutLa), hMLH1-hPMS1 (hMutLb), and hMLH1-hMLH3 (hMutLγ) (5). 
As a post-replication event, hMutS scans the new DNA strand looking for 
mismatches and loops of insertion or deletion. However, hMutSα more efficiently recognizes 
base–base mismatches and insertion/deletion mispairs in which one strand contains one or 
two unpaired nucleotides, whereas hMutSβ preferentially identifies loops of insertion/deletion 
of two to over 10 nucleotides (10). Following the recognition of a mispaired, hMutS 
undergoes an ATP-induced conformational change that activates it and promotes its 
interaction with hMutL proteins. Subsequently, Proliferating Cell Nuclear Antigen (PCNA) 
activates hMutL to incise the daughter strand hundreds of base distant from the mismatch. 
Once hMutL nicks the DNA, hMutS activates EXO1 (an exonuclease) to progressively excise 
the DNA containing the mismatch or the insertion/deletion loop, while DNA polymerases d/e 
initiate the new strand synthesis from the nicked point (11) (Fig. 1). 
However, MMR genes can also be disrupted by mutations or hypermethylations, 
predisposing cells to acquire an increased amount of DNA mismatches and potentially 
developing a neoplastic phenotype. This is better exemplified by Lynch syndrome and its 
increased incidence of hereditary non-polyposis colorectal cancer (HNPCC) (12). 
In addition, studies demonstrating abnormal expression of MMR components in 
breast (13), prostate (14), urothelial (15), and lung cancers (16) have also been described, 
usually showing a lower expression of MMR proteins. 
Similarly, alterations in the MMR complex have also been correlated with the 
onset and progression of oral potentially malignant lesions and OSCC, with some new 
evidences that these proteins could play a role as prognostic determinants (Table 1). All these 
studies support additional investigations to better understand the biological implication of 
MMR mutation and epigenetic modifications in the neoplastic context. 
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MMR expression in oral and lip potentially malignant lesions 
Leukoplakia is the most common potentially malignant lesion of the oral cavity, 
and several studies looked forward to assessing the MMR protein expression pattern in this 
lesion. Caldeira et al. (17) evaluated hMLH1 immunoexpression in different grades of 
dysplasia, demonstrating a lower expression in more dysplastic lesions. These results were 
confirmed by the same group that showed a lower expression of hMLH1 in more dysplastic 
OL, also revealing an inverse correlation with p53 and AgNOR expression (18). These 
authors suggested that hMLH1 alterations would represent an early molecular event in oral 
carcinogenesis, what was supported by Jessri et al. (19) who confirmed a reduced expression 
of hMLH1, hPMS2, and hMSH2 in OL and in OSCC when compared to normal oral mucosa, 
also attributing a diagnostic role for these proteins. Sengupta et al. (20) showed that the 
promoter regions of hMLH1 and hMSH2 were hypermethylated in 63% of their OL samples, 
and this epigenetic feature correlated with the presence of microsatellite instability in 
dysplastic cells and with tobacco use by the patients. Fernandes et al. (21) also described 
altered hMLH1 expression in oral epithelium associated with tobacco use, with a higher 
expression in smokers than non-smokers. 
Similar results were described for actinic cheilitis (AC), the most common 
potentially malignant lesion of the lip. Sarmento et al. (22) immunohistochemically analyzed 
forty cases of lower lip AC demonstrating that hMLH1 and hMSH2 were less expressed in 
more dysplastic lesions. These results were also obtained by Oliveira et al. (23) who showed 
higher expression of hMLH1 in AC with mild dysplasia, whereas Souza et al. (24) found a 
lower expression of hMSH2 in lip cancer than in AC. 
Taken together, currently available studies that investigated MMR proteins in oral 
and lip potentially malignant lesions have predominantly evaluated hMLH1 and hMSH2 
proteins, always using immunohistochemical technique. 
Although this methodology precludes the functional state of the proteins, most of 
the results suggest that they are downregulated in more dysplastic lesions, making patients 
more susceptible to additional DNA mutations and consequent malignant transformation. 
However, further analyses with different laboratorial techniques are necessary to confirm this 
assumption and to better understand the role played by MMR system in the pathogenesis of 
OL and AC. 
 
MMR expression in oral squamous cell carcinoma 
Oral cancer is the sixth most common malignancy in the world (25), and 
squamous cell carcinoma accounts for more than 90% of all cases (26). Different authors have 
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attempted to determine the importance of MMR proteins for OSCC pathogenesis, and Lo 
Muzio et al. (27) results represent one of the earliest evidences that a reduction in the 
expression of hMSH2 and hMLH1 could be associated with OSCC development. 
This initial observation was subsequently confirmed by Jessri et al. (19) that 
revealed a progressive reduction of hMLH1, hMSH2, and hPMS2 from mild, moderate, and 
severe dysplasia to OSCC. In a following study, Jessri et al. (25) further confirmed the lower 
expression of hMLH1, hMSH2, hPMS2, and hMSH6 in more dysplastic OL and even more in 
OSCC, also highlighting the diagnostic utility of hMSH6 in the identification of carcinoma in 
situ. Sarmento et al. (22) confirmed the lower expression of hMLH1 and hMSH2 in OSCC 
and Helal et al. (28) additionally identified a significant correlation between the low hMSH2 
and p53 expressions in OSCC, suggesting that hMSH2 would play a role in the late stages of 
oral carcinogenesis. 
In addition to mutational status of MMR proteins, their frequently described lower 
expression in OSCC can also be explained by epigenetic events. Czerninski et al. (29) 
demonstrated that 50% of their OSCC cases had hypermethylation of the promoter region of 
hMSH2 and hMLH1, similar to the results of González-Ramírez et al. (30) who observed that 
76% of their OSCC cases presented hyper- methylation of the promoter regions of hMLH1, 
whereas Sengupta et al. (20) showed that tobacco use increased susceptibility to hMLH1 and 
hMSH2 hypermethylation. Tawfik et al. (31) assessed the expression and the methylation 
pattern of hMLH1 promoter, observing that 30.6% of their Head and Neck Squamous Cell 
Carcinoma (HNSCC) cases (including oral cavity) presented a low hMLH1 expression, with 
86.7% of the cases having hypermethylation of the promoter region. On the other hand, Wang 
et al. (32) failed to correlate hMLH1 and hMSH2 methylation, exon mutation, and gene 
expression with the presence of microsatellite instability in patients with HNSCC. 
Genetic polymorphisms of MMR genes in patients affected by OSCC were also 
investigated, and some studies showed that single nucleotide polymorphism (SNP) of hMLH1 
and hMSH3 can be associated with OSCC predisposition (33, 34). Nogueira et al. (35) 
showed that inherited hMLH1 c.-93G>A, hMSH2 c.21119C>G, hMSH3 c.3133G>A, and 
EXO1 c.1765G>A polymorphisms are predictors of clinical outcomes of patients affected by 
HNSCC. 
Few authors attempted to demonstrate the clinical significance of MMR proteins 
in patients affected by OSCC. Cell lineages with low expression of hMSH2 and hMLH1 were 
shown to be more resistant to the chemotherapeutic effect of cisplatin (36, 37), whereas our 
recent study evidenced that lower hMSH2 expression was associated with higher T stage and 
that both hMSH2 and hMSH6 expression predicted a poor prognosis (38). 
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In contrast to the observed for potentially malignant lesions, although 
immunohistochemical studies still predominate in the evaluation of MMR system in OSCC, 
there are several genetic analyses currently available. However, functional assays and 
different in vitro and in vivo analyses are still necessary to fully understand the role of MMR 
proteins in the development of OSCC. Moreover, only one study investigated the prognostic 
potential of MMR proteins, demanding additional analyses. Finally, some reports used 
squamous cell carcinomas from different head and neck regions in their studies, what could 
preclude stronger conclusions given the biological heterogeneity of these lesions. On the other 
hand, available evidences point toward an important role played by the loss of MMR system 
to OSCC pathogenesis. 
 
MMR expression in other oral neoplasms 
Mismatch repair proteins have also been investigated in other oral neoplasms like 
in oral melanoma where hMLH1, hMSH2, hPMS1, and hPMS2 expressions were shown to be 
frequently decreased (39, 40). Regarding salivary gland tumors, Tobón-Arroyave et al. (41) 
suggested that the lower expression of hMLH1 and hMSH2 in cases of pleomorphic adenoma 
would indicate a higher risk for malignant transformation of this tumor. However, no 
significant differences were observed between benign and malignant salivary gland tumors in 
two other studies (42, 43), whereas salivary gland adenocarcinomas demonstrated higher 
expression of hMSH2 and hMLH1 when compared with pleomorphic adenomas in Castrilli et 
al. (43) investigation. These results demonstrate divergent conclusions regarding MMR 
proteins in salivary gland tumorigenesis. 
Regarding odontogenic tumors, MMR proteins were investigated only in 
ameloblastomas. Castrilli et al. (44) evaluated the expression of hMSH2 and hMLH1 proteins 
by immunohistochemistry in 25 cases, observing a nuclear positivity in all of them, 
speculating that the development and progression of ameloblastomas would not depend on a 
defect in the MMR system. 
 
Conclusion 
Mismatch repair system is an important group of proteins for DNA repair and 
maintenance of the genomic stability. Disruption of this system has been suggested to be 
important in the pathogenesis of different oral lesions, including potentially malignant 
disorders and malignant neoplasms. However, most of the studies currently available are 
limited to demonstrate the immunoexpression of these proteins (more frequently of hMSH2 
and hMLH1), and the size of the samples investigated is usually small, rarely correlating their 
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expression patterns with clinicopathological parameters. Therefore, although we have 
evidences that the loss of MMR proteins is important for the development of several oral 
lesions, further studies are warranted to better understand their importance as possible 
therapeutic targets, especially in the OSCC context, where these proteins also remain to be 
further validated as prognostic markers. 
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Figure 1: Schematic illustration of MMR system, exemplifying hMutSα (hMSH2 and 
hMSH6) and hMutLa (hMLH1 and hPMS2) function. (A) Mismatch base (red triangle) was 
incorporated in the DNA strand during replication and not recognized by DNA polymerase. 
(B) hMutSα recog- nized the error and recruited hMutLa to form a complex. (C) PCNA 
activates hMutLa endonuclease function to incise the daughter strand both distally and 
proximally to the mispairing position. (D) hMutSα activates EXO1 to remove the excised 
DNA containing the mismatch. (E) DNA polymerase with PCNA initiates the new DNA 
synthesis from the nicked region. 
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Table 1. Results obtained by the currently available studies that investigated MMR proteins in oral lesions. 
Authors Lesion investigated MMR proteins 
 investigated 
Main results obtained 
Fujieda et al., 
1998 
OSCC hMSH2 Lower expression of hMSH2 showed more resistance to 
cisplatin. 
Lo Muzio et al., 
1999 
OSCC hMSH2/hMLH1 Reduction of these proteins may be related with OSCC. 
Korabiowska et 
al., 1999 
Oral melanoma hMSH2/hMLH1/hPMS1/hPMS2 Lower expression correlated with high aneuploidy ratio. 
Lo Muzio et al., 
2000 
Oral melanoma hMSH2/hMLH1 Low expression of the proteins. 
Wang et al., 2001 OSCC hMLH1/hMSH2 There is no association between MMR proteins and MSI. 
Ohki et al., 2001 SGT hMSH2 hMSH2 expression is not significantly different between benign 
and malignant tumors. 
Castrilli et al., 
2001 
Ameloblastoma hMSH2/hMLH1 All cases were positive for the proteins. 
Castrilli et al., 
2002 
SGT hMSH2/hMLH1 hMSH2 and hMLH1 expressions are not significantly different 
between benign and malignant tumors. 
Sengupta et al., 
2007 
Leukoplakia/HNSCC hMSH2/hMLH1 Hypermethylation of the promoter regions and positive 
correlation with tobacco use. 
Czerninski et al., 
2009 
OSCC hMSH2/hMLH1 OSCC presented hypermethylation of hMSH2 and hMLH1 
promoters. 
Tobón-Arroyave 
et al., 2009 
PA hMSH2/hMLH1 Lower expression correlated with a higher risk for malignant 
transformation. 
Adachi et al., 
2010 
HNSCC hMLH1 Low expression of hMLH1 showed more resistance to cisplatin. 
Souza et al., 2011 AC hMSH2 Lower expression in severe dysplasia. 
González-
Ramírez et al., 
2011 
OSCC hMLH1 Presence of hypermethylation of hMLH1. 
Tawfik et al., HNSCC hMLH1 86.7% of the sample showed hypermethylation. 
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2011 
Caldeira et al., 
2011a 
Leukoplakia hMLH1 Lower expression in severe dysplasia. 
Caldeira et al., 
2011b 
Leukoplakia hMLH1 Lower expression in severe dysplasia. 
Helal et al., 2012 OSCC hMSH2 Lower expression in OSCC. 
Sarmento et al., 
2013 
AC/OSCC hMLH1/hMSH2 Lower expression in OSCC. 
Jha et al., 2013 OSCC hMLH1 Polymorphism in this gene may be related with OSCC 
predisposition. 
Mondal et al., 
2013 
Leukoplakia/OSCC hMSH3 Polymorphism in hMSH3 may be related with OSCC 
predisposition. 
de Oliveira et al., 
2014 
AC hMLH1 Lower expression in severe dysplasia. 
Nogueira et al., 
2015 
OSCC hMLH1/hMSH2/hMSH3/EXO1 Polymorphisms in the MMR system may be related with OSCC 
predisposition. 
Jessri et al., 
2015a 
OSCC hMSH2/hMSH6/hMLH1/hPMS2 Focal lack of hMSH6 indicates carcinoma in situ. 
Jessri et al., 
2015b 
Leukoplakia/OSCC hMSH2/hMSH6/hMLH1/hPMS2 Lower expression in severe dysplasia (except hMSH6). 
Wagner et al., 
2016 
OSCC hMSH2/hMSH6  Independent prognostic markers 
AC: Actinic cheilitis; PA: Pleomorphic adenoma; Oral squamous cell carcinoma; HNSCC: Head and neck squamous cell carcinoma; SGT: Salivary gland tumors.  
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2.2 Artigo: Prognostic significance of hMSH2, hMSH3 and hMSH6 expression in 
ameloblastoma 
Artigo aceito para publicação no periódico Oral Surgery, Oral Medicine, Oral Pathology, Oral 
Radiology. (Anexo 2) 
Gleyson Kleber do Amaral-Silva1, Celeste Sánchez-Romero1, Vivian Petersen Wagner2, 
Manoela Domingues Martins2, Hélder Antônio Rebelo Pontes3, Eduardo Rodrigues Fregnani4, 
Fernando Augusto Soares5, Oslei Paes de Almeida1, André Caroli Rocha6, Alan Roger 
Santos-Silva1, Felipe Paiva Fonseca7 and Pablo Agustin Vargas1 
1. Department of Oral Diagnosis - Piracicaba Dental School – University of Campinas 
(Piracicaba/Brazil) 
2. Department of Pathology - School of Dentistry - Federal University of Rio Grande do Sul 
(Porto Alegre/Brazil). 
3. Service of Buccal Pathology – João de Barros Barreto University Hospital – Federal 
University of Pará (Belém/Brazil). 
4. Oral Medicine Department – Sírio-Libanês Hospital (São Paulo/Brazil). 
5. Department of Pathology, A. C. Camargo Cancer Center (São Paulo/Brazil). 
6. Medical School, Clinics Hospital, University of São Paulo (São Paulo/Brazil). 
7. Department of Oral Surgery and Pathology – School of Dentistry – Universidade Federal 
de Minas Gerais (Belo Horizonte/Brazil). 
Corresponding Author: 
Prof. Dr. Pablo Agustin Vargas, FRCPath 
Piracicaba Dental School – University of Campinas (UNICAMP) 
Department of Oral Diagnosis – Oral Pathology 
Av. Limeira, 901 ZipCode: 13414-903  Piracicaba – São Paulo – Brazil 
Tel.: +55 19 21065319 E-mail: pvargas@fop.unicamp.br 
Conflict of interest statement 
The authors state that they have no potential conflict of interest that could bias the results 
obtained in this study. This research has been supported by grants from the São Paulo State 
Research Foundation (FAPESP 2015/21520-8). 
Word count for the abstract: 177 Manuscript word count: 3162 
Number of references: 44 Number of figures/tables: 6 figures and 1 table 
28 
 
Abstract 
Aims: To investigate hMutS proteins in human dental germ, ameloblastomas and 
ameloblastic carcinoma, and to determine whether the expression of these proteins has any 
prognostic potential. 
Methods and results: Ten cases of human dental germs, 39 ameloblastomas and 2 
ameloblastic carcinomas were used to determine the distribution of the proteins during the 
carcinogenesis process. Simultaneously, another sample of 73 ameloblastomas was arranged 
in tissue microarray and their clinical, microscopic and radiographic features, treatment 
outcome, presence of BRAF-V600E mutation and follow-up data, were assessed to determine 
the prognostic relevance of the proteins. Immunohistochemistry was performed using 
antibodies against hMutS (hMSH2, hMSH3, hMSH6) and Ki67. hMSH2 and hMSH6 were 
significantly down-expressed in ameloblastomas (p=0.0059) than in human dental germs 
(p<0.0001). hMSH2, hMSH3 and the protein combinations were significantly associated with 
BRAF-V600E mutation (p<0.05). Simultaneous over-expression of hMutS was associated 
with recurrences (p=0.035); however, the proteins did not predict the disease-free survival of 
patients (p>0.05). 
Conclusions: hMutS proteins are down-regulated in ameloblastoma; moreover, simultaneous 
over-expression of these proteins in ameloblastoma was associated with recurrence, but did 
not predict disease-free survival. 
 
Keywords: ameloblastoma; odontogenic tumors; hMSH2; hMSH3; hMSH6; mismatch 
protein. 
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Introduction 
Ameloblastoma is one of the most important odontogenic tumors given its high 
frequency, local aggressiveness and infiltrative potential1-3. Surgery remains the gold standard 
of treatment, ranging from conservative to aggressive approaches that lead to a recurrence rate 
varying from 6% to over 51%, and different degrees of morbidity.4 Although malignant 
odontogenic tumors are rarely identified, representing less than 6% of all odontogenic tumors, 
ameloblastic carcinoma is the most common subtype. It may arise de novo or secondarily to a 
previous benign ameloblastoma.5,6 Adult males are more affected and mandible is the most 
involved location.7 Wide surgical resection is the recommended management, but there is a 
recurrences rate of up to 90% and distant metastases are present in approximately 22% of the 
cases.5,7 
Ameloblastoma and ameloblastic carcinoma pathogenesis is poorly understood, 
but a growing number of studies have attempted to define the molecular events that may drive 
their development and clinical behavior. Recently, much attention has been paid to the 
Mitogen activated protein kinases (MAPK) pathway mutations, especially in the B-Raf 
(BRAF) oncogene,8–10 which was shown to be altered in approximately 60% of 
ameloblastomas, potentially determining an increased ameloblastoma aggressiveness.11 
In an attempt to avoid genetic mutations or decrease their frequency, humans 
contain a complex group of proteins organized in the so-called mismatch repair system 
(MMR), which is responsible for identifying and correcting mismatch and small loops of 
deletion and insertion in DNA bases.12,13 The MMR system consists of hMutS with its 
heterodimers hHMSH2-hMSH6 (called hMutSα) and hHMSH2-hMSH3 (called hMutSβ), and 
of hMutL with its heterodimers hMLH1-hPMS2 (hMutLα), hMLH1-hPMS1 (hMutLβ) and 
hMLH1-hMLH3 (hMutLγ).12 The failure in this system, either by mutations or by epigenetic 
events, may lead to the development of pathological conditions, including different human 
cancers,14,15 however, its importance for the pathogenesis of odontogenic tumors 
remainsunclear and demands to be better understood.16 Therefore, the aim of this study is to 
investigate the expression pattern of hMSH2, hMSH3 and hMSH6 in human dental germ, 
ameloblastomas and ameloblastic carcinomas, and to determine whether the expression of 
these proteins has any prognostic potential for patients affected by ameloblastomas. 
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Material and Methods 
Samples 
For investigating the different expression patterns of hMutS proteins in benign 
and malignant tumors and in their normal counterpart, 10 formalin-fixed paraffin-embedded 
human dental germs present in surgical specimens sent for microscopic analysis of other 
lesions, 39 cases of ameloblastomas and 2 cases of ameloblastic carcinomas were retrieved 
from the files of three Brazilian institutions (Federal University of Pará – Belém; Federal 
University of Rio Grande do Sul – Porto Alegre; and University of Campinas – Piracicaba) in 
a 12-year period from January 2003 to January 2015. New 5 μm histological sections stained 
with haematoxylin and eosin (H&E) were used to confirm the original diagnoses by two oral 
pathologists. Clinical data regarding sex, age, tumor location, predominant microscopic 
pattern and radiographic features were also retrieved from the patients’ dental charts. 
Simultaneously, another set of 93 cases of ameloblastomas with full 
clinicopathological data available (sex, age, tumor location, tumor size, tumor duration, 
vestibular/palatine cortical disruption, basal cortical disruption, predominant microscopic 
pattern, radiographic pattern, recurrences, follow-up data and BRAF-V600E 
immunohistochemical status) were retrieved from the files of the Department of Pathology of 
the A. C. Camargo Cancer Center (São Paulo – Brazil) and organized in a tissue microarray 
(TMA) block to investigate the prognostic potential of hMutS proteins. The disease-free 
survival (DFS) was obtained by calculating the time between the treatment date and the date 
of recurrence or the last follow-up data obtained.The study was approved by the Ethics 
Committee of the Piracicaba Dental School, University of Campinas (protocol 54172016.8). 
 
Tissue microarray 
The construction of the TMA block was previously described.11 Briefly, after the 
microscopic review of the 93 ameloblastoma cases, areas of interest in each case were 
selected from their respective H&E stained sections, and a TMA block was constructed 
(Beecher Instruments, Silver Springs, USA). The areas identified in the donor paraffin block 
were punctured twice with a 1.0 mm needle, and the two cylinders obtained were transferred 
to the receptor paraffin block. A case was considered appropriate when at least 25% of the 
total area of the cylinder with neoplastic tissue was available for analysis. Sequential 4 µm 
thick sections were cut and collected on adhesive slides. A map specifying the exact position 
of each core was made and a cylinder of normal liver tissue was included in the lower left 
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corner of the TMA block for orientation. TMA protocol used for this study was previously 
validated by our group.1 
 
Immunohistochemistry 
Immunohistochemical reactions were carried out in 3µm histological sections of 
all cases. Samples were dewaxed with xylene and then hydrated in an ethanol series. Antigen 
retrieval was performed using citrate solution (pH 6.0) in a pressure cooker for 3 minutes, and 
the endogenous peroxidase activity was blocked using 10% hydrogen peroxide. After washing 
in PBS buffer (pH7.4), slides were incubated overnight with primary antibodies against 
hMSH2 (Polyclonal, Santa Cruz Technology, California, USA, diluted 1:100), hMSH6 
(Polyclonal, Cell Marque, California, USA, diluted 1:50), hMSH3 (Polyclonal rabbit 
antihuman, Novus Biologicals, Newcastle, UK) and Ki-67 (Monoclonal, clone MIB1, 
DakoCytomation, Glostrup, Denmark, diluted 1:100). All slides were subsequently exposed 
toavidin-biotin complex, horseradish peroxidase reagents (LSAB Kit-DakoCytomation), and 
diaminobenzidine tetrahydrochloride (DAB, Sigma, St. Louis, MO, USA), and subsequently 
counter-stained with Carazzi haematoxylin. Positive control sections were used for each 
antibody, including colonic samples for hMSH2, hMSH3 and hMSH6, and oral squamous cell 
carcinoma (OSCC) samples for Ki-67. Negative controls were obtained by omitting the 
primary antibodies. 
 
Conventional quantitative analysis 
In the human dental germ, the 39 cases of ameloblastomas and the 2 ameloblastic 
carcinomas, the expression of hMSH2, hMSH3, hMSH6 and Ki-67 was obtained by one 
observer by counting the percentage of positive cells in a total of 1,000 cells per case in 
hotspot areas, using photomicrographs in 400x taken with a DFC345 Photomicroscope (Leica 
DMR, Leica Microsystems, Wetzlar, Germany) and assessed with ImageJ software (version 
1.51c, National Institutes of Health, Bethesda, MD, USA). 
 
Digital analysis 
The immunohistochemical reactions against hMSH2, hMSH3 and hMSH6 done in 
the ameloblastoma cases of the TMA sections were then scanned into high-resolution images 
using the Aperio Scanscope CS Slide Scanner (Aperio Technologies Inc, Vista, CA). The 
digital images obtained in .svs format were visualized using the ImageScope software (Aperio 
Technologies Inc., Vista, CA). hMSH2, hMSH3 and hMSH6 nuclear stainings were analyzed 
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using the Nuclear V9 algorithm (Aperio Technologies Inc, Vista, CA) with the following 
input parameters: averaging radius: 0.9; curvature threshold: 2.5; lower threshold: 0; upper 
threshold: 230; minimum nuclear size: 22; maximum nuclear size: 165; minimum roundness: 
0.3; minimum compactness: 0.1; minimum elongation: 0.2; clear area objective: 240; and an 
intensity threshold ranging from 0 to 230, in which strong staining was considered from 0 
to185 and weak staining was from 185 to 230. At least 1000 cells were quantified in each case 
and the percentage of positive cells was determined. 
 
Statistical analysis 
Initially, D’Agostino–Pearson test was used to determine the normality 
distribution of the obtained data. Subsequently, to compare the immunoexpression of hMSH2, 
hMSH3, hMSH6 and Ki67 between human dental germ and ameloblastoma, the unpaired 
Student t-test and Mann–Whitney test were used. To investigate the association of hMSH2, 
hMSH3 and hMSH6 with clinicopathological parameters, results were categorized as above 
and below the mean positivity and the two-tailed Fisher’s exact test and the chi-square test 
were used. Pearson and Spearman tests were used to investigate the correlation of hMSH2, 
hMSH3 and hMSH6 with the expression of Ki67. Survival analysis was calculated using the 
Kaplan–Meier method and the Log-rank univariate test was used to compare the groups. 
Because only two cases of ameloblastic carcinoma could be retrieved, the results obtained in 
this lesion were only descriptively described. GraphPad Prism version 5.01 (La Jolla, CA, 
USA) and IBM SPSS version 20 (Chicago, IL, USA) software were used for statistical 
analyses and a pvalue ≤ 0.05 using a 95% confidence interval was considered statistically 
significant. 
 
Results 
Expression of hMSH2, hMSH3, hMSH6 and Ki67 in human dental germ, ameloblastoma 
and ameloblastic carcinoma 
In the ameloblastoma cases, males and females were affected in 17 cases each, 
and in 5 cases the gender was not available. The mean age of this sample was 26 years (range 
20–30 years) and the posterior region of the mandible was the most affected (77% or 30 
cases) followed by the posterior region of maxilla (23% or 9 cases). Tumors predominantly 
presented as multilocular images (38% or 15 cases), whereas in 36% (14 cases) of the cases 
the radiographic exam revealed a unilocular image and in 25.6% of the cases data were not 
available (10 cases). Microscopically, 41% of the cases (16/39 cases) predominantly 
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presented the follicular pattern, whereas 59% of the cases (23/39 cases) predominantly 
presented the plexiform pattern. Due to its rarity, only two cases of ameloblastic carcinoma 
could be retrieved, one of them affecting a 28-year-old female patient whose details have been 
described previously17 and the other affecting the posterior mandible of a 23-year-old male 
patient. 
Evaluating hotspot areas of the epithelial component of the human dental germs a 
Ki67 proliferative index of 6.67% was obtained and positive cells were present both in the 
ameloblastic layer and in the central stellate reticulum area. In ameloblastomas the 
proliferative index was 3.76% and positive cells were predominantly located in the basal layer 
of the neoplastic epithelial nests. This variation was significantly different (p < 0.0005). The 
mean proliferative index of the ameloblastic carcinoma cases achieved 63% (Figure 1). 
The expression of hMSH2, hMSH3 and hMSH6 proteins was found in all 
investigated cases with similar distribution patterns, but different rates. All proteins were 
observed in both epithelial and mesenchymal compartments of the human dental germs. In the 
epithelial component the proteins were predominantly presented in the ameloblastic layer, 
although some cells in the stellate reticulum were also positively stained, achieving in the 
hotspot areas of the epithelium an immunoreactivity of 60.2%, 60.2% and 60.6% to hMSH2, 
hMSH3 and hMSH6, respectively (Figures 2A, 3A and 4A). In ameloblastoma cases, the 
proteins were also present in both peripheral and central areas of the neoplastic epithelial 
nests and strands. Positive nuclei of granular cells were rarely observed and the stromal cells 
were negative. Positivity in ameloblastomas achieved 43.2%, 59.5% and 40.9% to hMSH2, 
hMSH3 and hMSH6, respectively (Figures 2B, 3B and 4B). Although only two cases of 
ameloblastic carcinoma were analyzed, we observed a mean positivity of 38.5%, 39.5% and 
41.8% to hMSH2, hMSH3 and hMSH6, respectively, also lower than those observed in the 
normaltissue, but not too different from the benign tumor (Figures 2C, 3C and 4C). 
Statistically, we observed that the expression of all three proteins was decreased in 
ameloblastomas if compared to their normal counterpart, and significance was obtained for 
hMSH2 (p = 0.0059) and hMSH6 (p < 0.0001), whereas hMSH3 did not achieve statistical 
significance (p = 0.8836) (Figures 2D, 3D and 4D). Statistical analyses were not performed 
for ameloblastic carcinoma.  
The expression of hMSH2, hMSH3 and hMSH6 proteins did not correlate with 
Ki67 proliferative index in human dental germs (p = 0.56, p = 0.59 and p = 0.43, respectively) 
and in ameloblastomas (p = 0.50, p = 0.51 and p = 0.42, respectively). 
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Correlation of hHMSH2, hMSH3 and hMSH6 with clinicopathological and follow-up 
features of ameloblastoma 
To investigate whether the expression of hMSH2, hMSH3 and hMSH6 proteins 
would have any prognostic significance for patients affected by ameloblastoma, we used 
TMA sections initially containing 93 cases. However, because the TMA block had been used 
in previous studies and because of the aggressiveness of the immunohistochemical reactions 
to the neoplastic tissue, 73 cases remained in the TMA sections to be quantified. The 
clinicopathological and follow-up data regarding this final sample have been described 
previously.11 
All cases arranged in the TMA sections showed nuclear positivity for the three 
markers in both peripheral and central areas of the nest and islands, with no staining in the 
stromal cells. The sections were then digitized and the reactions quantified using the Nuclear 
V9 algorithm (Aperio Technologies Inc, Vista, CA), the results of which were categorized as 
above and below the mean positivity to be correlated with the clinicopathological parameters 
and follow-up status of the patients. Table 1 summarizes the results obtained. Briefly, we 
observed that hMSH2 and hMSH3 were significantly associated with cases presenting BRAF-
V600E mutation (p = 0.007 and p = 0.021, respectively) [data on BRAF V600E expression in 
this same sample have been previously described – Fregnani et al.11], whereas hMSH6 did not 
show any association. Moreover, when we organized the cases expressing high levels of 
hMSH2/hMSH3 (hMutSβ), hMSH2/hMSH6 (hMutSα) and hMSH2/hMSH3/hMSH6 
simultaneously, we also observed a significant association with BRAF-V600E status (p = 
0.009; p = 0.007 and p = 0.002, respectively). 
Although the expression of each protein individually did not demonstrate a 
significant association with the presence of recurrences, when all three proteins were 
simultaneously overexpressed a statistical significance was obtained (p = 0.035). No other 
significant association with clinicopathological parameters was found. Finally, using 
univariate analysis we were unable to find a significant difference in the DFS rates of patients 
with higher and lower expression of hMSH2, hMSH3, hMSH6 and their combinations (p > 
0.05), although it could be seen that in all these situations those patients with a lower 
expression presented a higher DFS rate (Figures 5 and 6). 
 
Discussion 
To avoid the accumulation of genetic mutations, humans count with a complex 
group of proteins that form the mismatch repair system (MMR), which is responsible for 
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identifying and correcting errors in the pairing process of nucleotide bases during the DNA 
replication.12,16 Here, we investigated the importance of hMutS proteins for ameloblastoma 
pathogenesis and behavior because the components of this system were shown to be 
deregulated in different human diseases14,18-24. Our results demonstrated that hMSH2 and 
hMSH3 expression is associated with BRAF-V600E mutation and that hMSH2, hMSH3 and 
hMSH6 simultaneous over-expression is associated with more recurrences, although the 
proteins did not predict the DFS rate of these patients.  
Very little is known about MMR proteins in odontogenic tumors. The only 
research in this context is from Castrilli et al.,25 which observed the expression of hMSH2 and 
hMLH1 in 25 ameloblastoma cases. However, the authors did not use a control group to 
determine whether the proteins were over- or down-expressed, and did not attempt to 
determine their clinical significance. In the present study, using a sample of human dental 
germs in different stages of development we observed that the proteins are down-regulated in 
ameloblastomas; moreover, the two cases of ameloblastic carcinoma also showed a lower 
expression of hMSH2, hMSH3 and hMSH6, suggesting that this system would be down-
regulated in the tumorigenesis process of ameloblastoma/ameloblastic carcinoma, possibly 
allowing the tumors to undergo more genetic mutations.  
Similar to our results, investigating oral carcinogenesis Jessri et al.19 observed a 
lower expression of hMLH1, hMSH2 and hPMS2 in OSCC than in oral leukoplakia, which 
has also been documented by Sarmento et al.26 during lip carcinogenesis. On the other hand, 
Xuan et al.27 observed an opposite distribution of hMSH2 during gall bladder carcinogenesis, 
describing a higher expression in the malignancy and a lower expression in its preceding 
nonneoplastic conditions. Taken together, these results suggest that the expression pattern of 
MMR molecules during human tumorigenesis may differ depending on the tissue analyzed. 
In accordance with some previous reports where hMutS proteins have not 
predicted the survival rates of patients affected by different neoplasms,28,29 we did not observe 
a correlation of hMutS expression patterns with prognostic factors in ameloblastoma either; 
nevertheless, Wagner et al.18 demonstrated a significant prognostic role for hMSH2 and 
hMSH6 in OSCC, Stark et al.30 found a prognostic potential for hMSH6 in glioblastoma and 
Perrin et al.31 also showed that hMSH2 is a prognostic indicator for colon cancer. Thus, our 
results and these studies illustrate the variable prognostic implications of MMR proteins in 
different human neoplasms.  
In some malignancies altered expression of MMR proteins was shown to be 
associated with clinicopathological parameters such as tumor size, lymph node metastasis, 
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clinical stage and chemotherapy resistance.18,32,33 In line with these reports, in our research a 
significant association was demonstrated between the simultaneous over-expression of 
hMSH2/hMSH3/hMSH6 and the presence of recurrences. As previously hypothesized,34 we 
may also speculate that cases presenting hMutS over-expression could carry other molecular 
events that would lead to a tumor with a higher potential of recurrences, stimulating the 
expression of hMutS proteins as an attempt to repair other genetic errors. Therefore, hMutS 
over-expression may represent an indicator of other molecular events. 
In the last few years new insights into the molecular characteristics of 
ameloblastoma have been obtained and different groups, including ours, have demonstrated 
the importance of BRAF-V600E mutation for ameloblastoma development and behavior.9,11,35 
Recent reports showed that 46 to 82% of ameloblastomas carry the BRAF-V600E 
mutation9,36,37 and using the same sample used in this study, we demonstrated that BRAF-
V600E immunoexpression seems to be an important determinant of aggressiveness.11 Here, 
we observed that except for hMSH6, the other proteins and their respective combinations 
were all significantly associated with the presence of BRAF-V600E mutation, but we cannot 
determine whether the presence of the BRAF mutation led to a higher expression of the 
proteins or whether the lower expression of hMutS proteins in ameloblastomas, if compared 
to human dental germs, would favor the occurrence of BRAF-V600E mutation. Interestingly, 
in colorectal cancer Miyakura et al.38 and Koinuma et al.39 had already demonstrated that 
BRAF somatic mutations are strongly associated with hMLH1 promoter methylation, whereas 
Waldmann et al.40 showed that BRAF-V600E mutation was present in 67% of their colorectal 
sample deficient for hMLH1 and Aparicio et al.41 showed that BRAF-V600E mutation was 
very frequent in elderly patients affected by colorectal cancer deficient for MMR proteins. 
These reports confirmed the importance of MMR system disturbance for the occurrence of 
BRAF mutationsin colorectal cancer, but more studies are necessary to determine whether this 
direct association is also true in ameloblastomas. 
We also investigated the possible correlation of hMutS proteins expression with a 
higher proliferative index measured by Ki67. Similar to previous analyzes that could not find 
a significant correlation between MMR proteins and the proliferative potential of other 
tumors,42 we did not obtain such correlation in ameloblastomas either. On the other hand, 
Helal et al.43 demonstrated a significant correlation of hMSH2 with p53 expression in OSCC 
and Köster et al.44 in breast cancer, suggesting that hMutS proteins would be more important 
for the control of the apoptosis of tumor cells than for their proliferative potential. 
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Despite the new data described in this study, it has the limitation of not having 
investigated the functional status of the proteins, not allowing us to determine whether this 
protein system is properly acting for DNA maintenance. Moreover, due to the rarity of 
ameloblastic carcinoma, only a very small sample could be used, precluding statistical 
analyzes and the acquisition of stronger results. 
In conclusion, hMutS proteins were down-regulated in ameloblastoma; moreover, 
simultaneous over-expression of these proteins in ameloblastoma was associated with 
recurrence, but did not predict disease-free survival. 
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Figures legends 
 
Figure 1. Ki67 expression. A) In the epithelial component of the human dental germs Ki67 
was predominantly observed in the peripheral palisade cells (DAB; 400x). B) Only some cells 
were positive in ameloblastoma, more commonly in the basal cells (DAB, 400x). C) In 
ameloblastic carcinoma Ki67 immunostaining was high and observed in peripheral and 
central areas of epithelial nests and strands (DAB, 400x). D) Ki67 immunoexpression was 
significantly higher in human dental germs than in ameloblastomas (Mann-Whitney test. p = 
0.0005). Because of the small sample size of ameloblastic carcinoma, statistical analysis could 
not be done for this group. 
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Figure 2. hMSH2 expression. A) Nuclear expression of hMSH2 protein in human dental 
germs (DAB, 400x). B) In ameloblastoma the nuclear expression was seen both in the 
peripheral and central areas of the neoplastic islands and strands (DAB, 400x). C) hMSH2 
was also observed in ameloblastic carcinomas (DAB, 400x). D) hMHS2 was significantly 
reduced in ameloblastomas than in human dental germs (Mann-Whitney test. p = 0.0059). 
Because of the small sample size of ameloblastic carcinoma, statistical analysis could not be 
done for this group. 
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Figure 3. hMSH3 expression. A) Positive expression in human dental germs (DAB, 400x). B) 
Nuclear positivity in both peripheral and central cells of neoplastic islands and strands of 
ameloblastoma (DAB, 400x). C) Both cases of ameloblastic carcinomas were also positive for 
the protein (DAB, 400x). D) There was no significant difference in the expression of hMSH3 
between human dental germs and ameloblastoma (Unpaired Student t-Test. p = 0.8836). 
Because of the small sample size of ameloblastic carcinoma, statistical analysis could not be 
done for this group. 
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Figure 4. hMSH6 expression. A) Peripheral and central cells of the epithelial component of 
human dental cells were positive for hMSH6 (DAB, 400x). B) Ameloblastoma was diffusely 
positive (DAB, 400x). C) In ameloblastic carcinoma positivity was seen in both cases 
analyzed (DAB, 400x). D) hMSH6 expression was significantly reduced in ameloblastomas 
than in human dental germs (Unpaired Student t-Test. p < 0.0001). Because of the small 
sample size of ameloblastic carcinoma, statistical analysis could not be done for this group. 
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Figure 5. Analysis of hMSH2, hMSH3 and hMSH6 expressions as prognostic determinants 
for patients affected by ameloblastoma. Results showed that patients expressing lower levels 
of the proteins presented higher survival rates, but not significantly different from those 
expressing higher levels of the proteins. A) High and B) low expression of hMSH2 in 
ameloblastomas. C) Kaplan-Meyer survival curves were not statistically different according 
to Log-rank univariate analysis (p = 0.137). D) High and E) low expression of hMSH3 in 
ameloblastomas. F) Survival curves were not significantly different (p = 0.627). G) High and 
H) low expression of hMSH6 in ameloblastomas. I) No statistical difference was seen 
between survival rates of patients expressing different levels of this protein (p = 0.543). Using 
digital analysis, blue nuclei represent negative cells and orange nuclei represent positive cells. 
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Figure 6. Analysis of the importance of hMSH2, hMSH3 and hMSH6 combination for 
determining the survival rates of patients affected by ameloblastomas. Although patients 
expressing higher levels of the proteins exhibited a shorter survival than those expressing 
lower levels of the proteins combined, no statistical significance could be obtained using the 
univariate analysis. A) Survival curves obtained when hMSH2 and hMSH3 were 
simultaneously over-expressed (p = 0.495). B) Survival curves obtained when hMSH2 and 
hMSH6 were simultaneously over-expressed (p = 0.180). C) Survival curves obtained when 
hMSH2, hMSH3 and hMSH6 were simultaneously over-expressed (p = 0.148). 
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Table 1. Analysis of the association between clinicopathological parameters obtained from the 73 cases of ameloblastoma with the expression of 
hMSH2, hMSH3, hMSH6 and their combination (Chi-square and Fisher’s exact tests). 
 hMSH2 hMSH3 hMSH6 hMSH2/hMSH3 hMSH2/hMSH6 hMSH2/hMSH3/hMSH6 
Sex p = 0.890 
 
p = 0.402 
 
p = 0.629 
 
p = 0.569 
 
p = 1.000 
 
p = 0.673 
 
Age p = 0.834 
 
p = 0.687 
 
p = 0.207 
 
p = 0.456 
 
p = 0.336 
 
p = 0.533 
 
Tumor site p = 0.784 
 
p = 0.720 
 
p = 0.664 
 
p = 0.724 
 
p = 0.203 
 
p = 0.661 
 
Tumor size p = 0.344 
 
p = 0.161 
 
p = 0.091 
 
p = 0.863 
 
p = 0.794 
 
p = 0.726 
 
Tumor duration p = 0.192 
 
p = 0.538 
 
p = 0.925 
 
p = 0.105 
 
p = 0.833 
 
p = 0.582 
 
Microscopic features p = 0.340 
 
p = 0.517 
 
p = 0.411 
 
p = 0.706 
 
p = 0.461 
 
p = 0.249 
 
Radiographic features p = 0.535 
 
p = 0.873 
 
p = 0.492 
 
p = 0.628 
 
p = 0.592 
 
p = 0.503 
 
Vestibular/palatine cortical 
disruption 
p = 0.819  
 
p = 0.576  
 
p = 0.325  
 
p = 0.857  
 
p = 0.358  
 
p = 0.456  
 
Basal cortical disruption 
 
p = 0.594 
 
p = 0.346 
 
p = 0.191 
 
p = 0.365 
 
p = 0.218 
 
p = 0.218 
 
Recurrences p = 0.106  
 
p = 0.417  
 
p = 0.227  
 
p = 0.368 p = 0.056  
 
p = 0.035* 
 
BRAF V600E status p = 0.007* p = 0.021*  p = 0.077 p = 0.009*  
 
p = 0.007*  
 
p = 0.002*  
* Statistically significant p value. 
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3 DISCUSSÃO 
O ameloblastomas é o principal tumor odontogênico benigno comumente 
diagnosticado nos serviços de diagnóstico oral (Nalabolu et al., 2017). Apresenta 
características de agressividade local, além de índice importante de recorrência baseado na 
modalidade terapêutica empregada. A progressão do tumor para o carcinoma ameloblástico 
secundário é possível, apesar de ser uma ocorrência rara (Dhanuthai et al., 2012; Milman et 
al., 2016). Assim como outros estudos, nos identificamos uma predominância do padrão 
histológico sólido nas amostras de ameloblastomas (Dhanuthai et al., 2012; Fregnani et al., 
2010). 
Os mecanismos de desenvolvimento destes tumores ainda não estão 
suficientemente definidos, embora recentes estudos tenham identificado a expressão da 
mutação BRAF-V600E em ameloblastomas, associando sua presença com o maior potencial 
de agressividade do tumor (Fregnani et al., 2016). Esta mutação corresponde à substituição do 
aminoácido valina (V) por ácido glutâmico (E) em decorrência da inserção de um nucleotídeo 
timina no lugar de adenina no códon 600, gerando um mismatch do tipo transversão de 
purinas (Davies et al., 2002). De acordo com Rossetti et al. (2015), este erro de pareamento é 
o mais crítico por criar pontes de hidrogênio promiscuas. 
Como avaliado em nossa primeira publicação, os seres humanos possuem um 
sistema de proteínas homólogo ao identificado nas bactérias E. coli, onde apresentam a função 
de identificação de erros de pareamento correto das bases do DNA após a replicação, além de 
inserção ou deleção de bases. Nosso estudo também demostrou uma variedade de lesões orais 
que apresentam alterações importantes nos níveis de expressão destas proteínas (Amaral-Silva 
et al., 2017). 
No nosso segundo estudo nós identificamos a expressão imunohistoquímica das 
proteínas hMutS em germes dentais humanos normais, bem como a redução progressiva desta 
expressão em ameloblastomas, com exceção da proteína hMSH3 (p = 0.8836). Não foi 
possível obter uma análise estatística desta relação com o carcinoma ameloblástico devido ao 
número reduzido de amostras (n = 2). Os casos de ameloblastomas que apresentaram 
sobrexpressões das proteínas hMSH2 e hMSH3 isoladamente mostraram significativa 
associação com a presença da mutação BRAF-V600E (p = 0.007 e p = 0.021, 
respectivamente). Quando analisada a expressão simultânea de hMSH2/hMSH3 (hMutSβ), 
hMSH2/hMSH6 (hMutSα) e hMSH2/hMSH3/hMSH6, também encontramos a associação 
com BRAF-V600E (p = 0.009; p = 0.007 e p = 0.002, respectivamente). 
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Alguns autores relacionam a deficiência de proteínas MMR com BRAF-V600E 
em câncer colorretal esporádico, correlacionando os achados com o prognóstico e tempo de 
sobrevida (Aparicio et al., 2014; Luey et al., 2014; Sinicrope et al., 2016; Toon et al., 2014; 
Waldmann et al., 2015; Wang et al., 2016). Nós encontramos que, apenas de reduzidas, as 
sobrexpressões simultâneas em relação as médias das proteínas hMSH2/hMSH3/hMSH6 
apresentaram, além da relação estatística com BRAF-V600E, uma importante correlação 
clínica com a presença de tumores recorrentes. 
Assim como Theocharis et al. (2011), nós acreditamos que a sobrexpressão de 
hMutS poderiam estar estimulada diante de outros eventos moleculares associados ao 
potencial de recorrência, na tentativa de reparar possíveis erros de pareamento de bases desses 
gens também sobrexpressos.  
Não houve correlação estatística relevante entre a expressão das proteínas hMutS 
e Ki67. Apenas observamos que a nossa expressão média de Ki67 nos ameloblastomas 
(3,76%) estava um pouco abaixo da faixa relatada por Meer et al. (2003) (entre 4,6% a 8,8%). 
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4 CONCLUSÃO 
Com base nos resultados obtidos em nosso estudo, podemos concluir que: 
1) Alterações no sistema mismatch estão presentes em diversas formas de 
condições potencialmente malignas e em neoplasias humanas. A ausência 
da expressão das suas proteínas são fatores diagnósticos para a Síndrome 
de Lynch. Muitas condições patológicas apresentam redução na expressão 
das proteínas, sendo isso potencialmente relacionado com eventos 
epigenéticos; 
2) A expressão imunohistoquímica média das proteínas hMutS estão 
sequencialmente reduzidas no ameloblastoma e no carcinoma 
ameloblástico em relação ao epitélio odontogênico do germe dental 
humano normal; 
3) A sobrexpressão das proteínas hMutS no ameloblastoma, sejam em 
conjunto ou isoladas (exceto hMSH6), apresentam relação estatisticamente 
significante com a presença da mutação BRAF-V600E; 
4) A sobrexpressão simultânea das proteínas hMSH2/hMSH3/hMSH6 em 
ameloblastomas apresentam potencial indicador para a recorrência 
tumoral. 
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